Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 16.9% in December

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 1,438 shares, a decrease of 16.9% from the November 30th total of 1,731 shares. Currently, 1.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,058 shares, the days-to-cover ratio is currently 1.4 days. Based on an average daily trading volume, of 1,058 shares, the days-to-cover ratio is currently 1.4 days. Currently, 1.3% of the shares of the stock are sold short.

Amplify Weight Loss Drug & Treatment ETF Price Performance

Amplify Weight Loss Drug & Treatment ETF stock traded down $0.20 during mid-day trading on Wednesday, hitting $25.25. The company’s stock had a trading volume of 4,512 shares, compared to its average volume of 1,965. The business has a 50 day moving average price of $24.80 and a 200-day moving average price of $23.73. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $18.56 and a 12 month high of $26.30. The stock has a market cap of $2.78 million, a price-to-earnings ratio of 24.31 and a beta of 0.61.

Amplify Weight Loss Drug & Treatment ETF Announces Dividend

The company also recently declared an annual dividend, which will be paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th will be issued a dividend of $0.4132 per share. This represents a yield of 162.0%. The ex-dividend date is Tuesday, December 30th.

Institutional Trading of Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC raised its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.